Publicação

Equity research - Johnson & Johnson

Ver documento

Detalhes bibliográficos
Resumo:This paper, “Equity Research: Johnson & Johnson”, is according to ISEG’s guidelines for a Master’s Final Work, includes different valuation techniques, and brings awareness to potential investment risks. Johnson & Johnson is the third largest pharmaceutical company by market capitalization. The company was founded more than 130 years ago with the intent of improving healthcare. Since then, the company pioneered many products and innovations in the field, with the introduction to the market of products like band-aids and first-aid kits. Today, the company advances the progress made in the pharmaceutical sector. After researching and valuing the company, I conclude that the decision for investment is to HOLD, with a price target of $180.62 per share by 2023 YE, indicating an upside potential of 14.6%, when compared with the closing price of $157.64 on the 6th of October 2023, by using the Discounted Cash Flow (DCF) approach, Weighted Average Cost of Capital (WACC), Flow to Equity (FTE), and Adjusted Present Value (APV) methods. During the analysis, other methods were used, such as Dividend Discount Model (DDM), and Relative Valuation. I also assessed Johnson & Johnson’s investment risk as Medium, and the reports further explain this decision. The data used in this report was used until the date of 6th of October 2023.
Autores principais:Leite, João Aires Marinho Marreiros
Assunto:Johnson & Johnson Pharmaceutical Industry Research and Development Risk Valuation Johnson & Johnson Equity Research Indústria Farmacêutica Investigação e Desenvolvimento Risco Avaliação
Ano:2023
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade de Lisboa
Idioma:inglês
Origem:Repositório da Universidade de Lisboa

Registos relacionados

Registos relacionados